OpenAI unveiled a specialized artificial intelligence system Thursday aimed at advancing biological research and accelerating medical breakthroughs.
The new technology, called GPT-Rosalind in honor of renowned 20th-century British scientist Rosalind Franklin, focuses specifically on supporting scientific work in biochemistry, pharmaceutical development, and medical research translation.
Pharmaceutical companies, universities, and biotechnology firms have increasingly sought AI-powered solutions to speed up research processes and drug development timelines.
“By supporting evidence synthesis, hypothesis generation, experimental planning, and other multi-step research tasks, this model is designed to help researchers accelerate the early stages of discovery,” OpenAI said in a blog.
According to company officials during a press briefing, scientists can use the system to search scientific databases, analyze current research publications, integrate additional scientific tools, and receive recommendations for new experimental approaches. The technology builds upon OpenAI’s most advanced internal systems.
The research tool is currently accessible through ChatGPT, Codex, and the company’s API for approved users via OpenAI’s secure access program. Additionally, the company has released a complimentary Life Sciences research plugin for Codex that connects researchers to more than 50 scientific tools and data repositories.
OpenAI reports partnerships with major companies including Amgen, Moderna, and Thermo Fisher Scientific to integrate GPT-Rosalind into their research operations.
This announcement follows Tuesday’s release of GPT-5.4-Cyber, another specialized version of OpenAI’s technology focused on cybersecurity defense, which came after competitor Anthropic introduced its own advanced AI system called Mythos.
